8-(1H-indazol-5-yl)-1-cyclopropyl-7,9-dimethyl-4-oxo-4H-quinolizine-3-carboxylic acid | 1392845-35-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 8-(1H-indazol-5-yl)-1-cyclopropyl-7,9-dimethyl-4-oxo-4H-quinolizine-3-carboxylic acid
• 英文别名: 1-cyclopropyl-8-(1H-indazol-5-yl)-7,9-dimethyl-4-oxoquinolizine-3-carboxylic acid
• CAS: 1392845-35-0
• 化学式: C₂₂H₁₉N₃O₃
• 分子量: 373.411
• InChiKey: IJEBEQPEOHNSMH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  86.3
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] ANTIMICROBIAL 4-OXOQUINOLIZINES<br/>[FR] 4-OXOQUINOLIZINES ANTIMICROBIENNES
  申请人：EVOLVA SA

  公开号：WO2012104305A1

  公开（公告）日：2012-08-09

  This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.

  这项发明提供了新颖的4-氧喹啉化合物及其用途，用于一系列广谱抗生素，不会产生对现有或新出现的抗生素类别的交叉耐药性。此外，这些新颖的4-氧喹啉化合物对CDC A类和B类病原体具有作用。该发明还提供了包含某些4-氧喹啉与亚抑菌浓度的多粘菌素B结合的药物组合物，用于对抗对喹诺酮、碳青霉烯和其他抗微生物药物产生耐药性的临床分离株。
• ANTIMICROBIAL 4-OXOQUINOLIZINES
  申请人：Heim Jutta

  公开号：US20130252882A1

  公开（公告）日：2013-09-26

  This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.

  该发明提供了新型的4-氧喹啉并化合物及其用途，适用于一系列广谱抗生素，不与现有或新出现的抗生素类别产生交叉耐药性。此外，新型的4-氧喹啉并化合物对CDC A和B类病原体也有用。该发明还提供了包含某些4-氧喹啉并化合物与亚抑制浓度的多粘菌素B的药物组合，用于对抗对喹诺酮、碳青霉烯和其他抗微生物药物产生耐药性的临床分离株。
• Antimicrobial 4-oxoquinolizines
  申请人：Emergent Product Development Gaithersburg Inc.

  公开号：US10155021B2

  公开（公告）日：2018-12-18

  This invention provides novel 4-oxoquinolizine compounds and their uses for a series of broad-spectrum antibiotics having no cross-resistance to existing or emerging classes of antibiotics. In addition the novel 4-oxoquinolizine compounds are useful against CDC Category A and B pathogens. The invention also provides pharmaceutical compositions comprising certain 4-oxoquinolizines in combination with subinhibitory concentrations of polymyxin B against clinical isolates which are resistant to quinolones, carbapenems and other antimicrobial agents.

  本发明提供了新型 4-oxoquinolizine 化合物及其在一系列广谱抗生素中的用途，这些抗生素对现有或新出现的抗生素类别没有交叉抗药性。此外，新型 4-oxoquinolizine 化合物还可用于抗 CDC A 类和 B 类病原体。本发明还提供了由某些 4-氧代喹嗪类化合物与亚抑制浓度的多粘菌素 B 组合而成的药物组合物，用于抗击对喹诺酮类、碳青霉烯类和其他抗菌剂耐药的临床分离菌。
• US9403818B2
  申请人：——

  公开号：US9403818B2

  公开（公告）日：2016-08-02